Emerging Cancer Therapy

ARSÉNIO FIALHO, PHD, is Associate Professor in the Department of Chemical and Biological Engineering and Principal Investigator for the Institute of Biotechnology and Bioengineering in the Instituto Superior Técnico at the Universidade Técnica de Lisboa, Portugal. His current scientific interests are focused on the study of bacterial proteins, such as azurin and Laz, as novel multi-targeted drug candidates with anticancer activities. He is the author or coauthor of more than fifty papers in peer-reviewed scientific journals and, during the last four years, became the holder of five U.S. patents. Dr. Fialho teaches courses in biochemistry, molecular biology, and bioinformatics. ANANDA CHAKRABARTY, PHD, is Distinguished University Professor in the Department of Microbiology and Immunology at the University of Illinois College of Medicine at Chicago. In addition to more than 250 research publications, he has secured nine U.S. patents during the last four years on azurin and Laz, two bacterial proteins with anticancer, anti-viral and anti-parasitic activities. He also is the recipient of a patent on the first life form, a genetically manipulated pseudomonad designed to degrade multiple hydrocarbons present in crude oil, as decided by the U.S. Supreme Court in 1980 in the celebrated court case Diamond v. Chakrabarty.

• Preface ixContributors xiPart I Live/Attenuated Bacteria and Viruses as Anticancer Agents 11 Salmonella Typhimurium Mutants Selected to Grow Only in Tumors to Eradicate Them in Nude Mouse Models 3Robert M. Hoffman2 The Use of Living Listeria Monocytogenes as an Active Immunotherapy for the Treatment of Cancer 13John Rothman, Anu Wallecha, Paulo Cesar Maciag, Sandra Rivera, Vafa Shahabi, and Yvonne Paterson3 Bacillus Calmette–Guerin (BCG) for Urothelial Carcinoma of the Bladder 49Timothy P. Kresowik and Thomas S. Griffith4 Live Clostridia: A Powerful Tool in Tumor Biotherapy 71Lieve Van Mellaert, Ming Q Wei, and Jozef Anné5 Bifi dobacterium as a Delivery System of Functional Genes for Cancer Gene Therapy 99Geng-Feng Fu, Yan Yin, Bi Hu, and Gen-Xing Xu6 Replication-Selective Viruses for the Treatment of Cancer 119Padma Sampath and Steve H. Thorne7 Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy 141Jason S. Buhrman, Tooba A. Cheema, and Giulia FulciPart II Bacterial Products as Anticancer Agents 1798 Promiscuous Anticancer Drugs from Pathogenic Bacteria: Rational Versus Intelligent Drug Design 181Arsénio M. Fialho and Ananda M. Chakrabarty9 Arginine Deiminase and Cancer Therapy 199Lynn Feun, M. Tien Kuo, Ming You, Chung Jing Wu, Medhi Wangpaichitr, and Niramol Savaraj10 Cytosine Deaminase/5-Fluorocytosine Molecular Cancer Chemotherapy 219Sergey A. Kaliberov and Donald J. Buchsbaum11 Bacterial Proteins against Metastasis 243Anna Maria Elisabeth Walenkamp12 Pseudomonas Exotoxin A-Based Immunotoxins for Targeted Cancer Therapy 269Philipp Wolf and Ursula Elsässer-Beile13 Denileukin Diftitox in Novel Cancer Therapy 289Lin-Chi Chen and Nam H. Dang14 The Application of Cationic Antimicrobial Peptides in Cancer Treatment: Laboratory Investigations and Clinical Potential 309Ashley L. Hilchie and David W. Hoskin15 Prodiginines and Their Potential Utility as Proapoptotic Anticancer Agents 333Neil R. Williamson, Suresh Chawrai, Finian J. Leeper, and George P.C. Salmond16 Farnesyltransferase Inhibitors of Microbial Origins in Cancer Therapy 367Jingxuan Pan and Sai-Ching Jim Yeung17 The Use of RNA and CpG DNA as Nucleic Acid-Based Therapeutics 379Jörg VollmerPart III Patents On Bacteria/Bacterial Products as Anticancer Agents 40318 The Role and Importance of Intellectual Property Generation and Protection in Drug Development 405Arsénio M. Fialho and Ananda M. ChakrabartyIndex 421